Other single compounds
Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
32314704 2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
32378737 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?
Azithromycin
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
Doxycycline
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen
Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19
Chlorpromazine retarget
Lauric acid nat. compd.
Nicotine nat. toxin
32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking
Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
Various Leads
- 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
- paper in nature
32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
Camostat mesilate
32347443 ä. Camostat mesilate therapy for COVID-19
Nafamostat mesilate
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients
alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy
Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?
Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review
TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection
Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
Colchicine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32380315 ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19
Dextrometorphan
Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management
tPA
| 32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |
Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
Metformin
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors
Alisporivir
| 32376613 2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |
Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Bee venom
32360140 ä. Bee venom and SARS-CoV-2
Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19
Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
alpha 1 antagonists cave fehlt 1 x
bradykinin antagonists cave felt was
| 32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
